As of 2024-07-27, the EV/EBITDA ratio of Oramed Pharmaceuticals Inc (ORMP) is -8.94. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ORMP's latest enterprise value is 119.10 mil USD. ORMP's TTM EBITDA according to its financial statements is -13.32 mil USD. Dividing these 2 quantities gives us the above ORMP EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.6x - 17.1x | 13.3x |
| Forward P/E multiples | 17.2x - 21.3x | 20.4x |
| Fair Price | (5.97) - (5.92) | (5.85) |
| Upside | -329.6% - -327.8% | -324.8% |
| Date | EV/EBITDA |
| 2024-07-26 | -8.94 |
| 2024-07-25 | -8.76 |
| 2024-07-24 | -8.88 |
| 2024-07-23 | -9.03 |
| 2024-07-22 | -8.91 |
| 2024-07-19 | -8.79 |
| 2024-07-18 | -8.70 |
| 2024-07-17 | -8.85 |
| 2024-07-16 | -8.82 |
| 2024-07-15 | -8.73 |
| 2024-07-12 | -8.70 |
| 2024-07-11 | -8.61 |
| 2024-07-10 | -8.61 |
| 2024-07-09 | -8.64 |
| 2024-07-08 | -8.70 |
| 2024-07-05 | -8.82 |
| 2024-07-03 | -8.76 |
| 2024-07-02 | -8.87 |
| 2024-07-01 | -8.82 |
| 2024-06-28 | -8.85 |
| 2024-06-27 | -9.19 |
| 2024-06-26 | -8.85 |
| 2024-06-25 | -7.84 |
| 2024-06-24 | -7.81 |
| 2024-06-21 | -8.03 |
| 2024-06-20 | -7.75 |
| 2024-06-18 | -7.97 |
| 2024-06-17 | -7.84 |
| 2024-06-14 | -7.88 |
| 2024-06-13 | -7.98 |
| 2024-06-12 | -8.12 |
| 2024-06-11 | -7.33 |
| 2024-06-10 | -7.51 |
| 2024-06-07 | -7.42 |
| 2024-06-06 | -7.66 |
| 2024-06-05 | -7.75 |
| 2024-06-04 | -7.60 |
| 2024-06-03 | -7.75 |
| 2024-05-31 | -7.66 |
| 2024-05-30 | -7.84 |
| 2024-05-29 | -7.66 |
| 2024-05-28 | -7.72 |
| 2024-05-24 | -8.15 |
| 2024-05-23 | -8.09 |
| 2024-05-22 | -8.03 |
| 2024-05-21 | -8.06 |
| 2024-05-20 | -8.24 |
| 2024-05-17 | -8.03 |
| 2024-05-16 | -8.12 |
| 2024-05-15 | -8.30 |